Jacobio Pharmaceuticals Group Co., Ltd. disclosed a share buy-back executed on 14 May 2026 under its Hong Kong mandate dated 10 June 2025. The company repurchased 80,700 ordinary shares on the Stock Exchange at prices ranging from HK$5.60 to HK$5.63, translating into a volume-weighted average cost of HK$5.62 per share and an aggregate consideration of HK$0.45 million.

Following the transaction, Jacobio’s issued share capital (excluding treasury shares) declined marginally to 784.69 million shares, a 0.0103% reduction from the previous balance of 784.77 million shares. Treasury shares increased to 7.07 million, while total issued shares remained unchanged at 791.76 million.

Since receiving the 10 June 2025 shareholder authorisation permitting the repurchase of up to 78.87 million shares, the company has bought back 4.05 million shares, representing 0.51% of the shares outstanding on the mandate date. All repurchased shares to date have been retained as treasury stock.

Under Main Board Rule 10.06(3)(a), Jacobio is subject to a moratorium on issuing new shares or disposing of treasury shares until 13 June 2026.